FDA Clearance Tracker · P940035-S008
ALERE NMP22 BLADDERCHECK TEST & CONTROL KIT
Last checked: Nov 20, 2026Latest source record: Mar 21, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Mar 21, 2012
Approved
Time to decision
485 days
Received Nov 22, 2010. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P940035-S008
- Device name
- ALERE NMP22 BLADDERCHECK TEST & CONTROL KIT
- Applicant
- Abbott Diagnostics Scarborough, Inc.
- Applicant location
- Scarborough, ME
- Received
- Nov 22, 2010
- Decided
- Mar 21, 2012
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P940035
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE INTENT TO MANUFACTURE THE NMP22 BLADDERCHEK TEST AND NMP22 BLADDERCHEK CONTROL KIT UNDER ALERE SCARBOROUGH, INC. BRAND NAME. THE DEVICES, AS MODIFIED, WILL BE MARKETED UNDER THE FOLLOWING TRADE NAME: ALERE NMP22 BLADDERCHEK TEST, WITH THE FOLLOWING INTENDED USE: THE ALERE NMP22 BLADDERCHEK TEST IS AN IN VITRO IMMUNOASSAY INTENDED FOR THE QUALITATIVE DETECTION OF THE NUCLEAR MITOTIC APPARATUS PROTEIN (NUMA), WHICH IS AN ABUNDANT COMPONENT OF THE NUCLEAR MATRIX PROTEINS, IN URINE OF PERSONS WITH RISK FACTORS OR SYMPTOMS OF BLADDER CANCER OR WITH A HISTORY OF BLADDER CANCER. THIS TEST IS INDICATED FOR PROFESSIONAL USE AND PRESCRIPTION HOME USE AS AN AID IN DIAGNOSING AND MONITORING BLADDER CANCER PATIENTS, IN CONJUNCTION WITH STANDARD DIAGNOSTIC PROCEDURES.ALERE NMP22 BLADDERCHEK CONTROL KIT, WITH THE FOLLOWING INTENDED USE: ALERE NMP22 BLADDERCHEK CONTROL KIT IS DESIGNED TO PROVIDE THE USERS OF THE ALERE NMP22 BLADDERCHEK TEST WITH ADDITIONAL, OPTIONAL, QUALITY CONTROLS FOR OPERATING THE TEST.
Source documents
Other decisions for Abbott Diagnostics Scarborough, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262747 · Decided Aug 31, 2026 · 28 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.